Stevens will remain a director and continue to serve on the board, the Vancouver-based company said in a statement.
“Anne and I co-founded Aequus together and I want to thank her for her many contributions over the years,” said CEO Doug Janzen. “Anne is an incredibly talented and effective executive who is leaving the company in excellent shape and well-positioned for success in the years to come. We are excited about her future plans and look forward to her continued work with the Aequus Board.”
READ: Aequus and partner Medicom Healthcare win Medical Device License for Evolve Intensive Gel to treat Dry Eye Disease
Stevens added: “It is extraordinary to see how Aequus has grown to be the mature commercial entity it is today, with a sharp focus and great momentum towards being a meaningful contributor to the Eye Care landscape in Canada. I believe that the commercial team is well prepared for my departure under the leadership of Grant Larsen and I look forward to watching a strong launch of the Evolve line of eye care products in Canada.”
Aequus and its partner Medicom Healthcare Ltd have been issued a new Medical Device License for the first of three product submissions for the Evolve preservative-free dry eye product line.
The Evolve Intensive Gel – a unique cross-linked combination of Carbomer 980, Hyaluronate and glycerol – provides intensive, durable hydration for patients with moderate to severe forms of Dry Eye Disease. The formulation will be made available in an easy-squeeze eye drop bottle containing 360 drops, and no preservatives, phosphates, or buffers.
Contact the author: email@example.com
Follow him on Twitter @PatrickMGraham